Iterum Therapeutics (ITRM) Set to Announce Quarterly Earnings on Thursday

Iterum Therapeutics (NASDAQ:ITRM) will be issuing its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Iterum Therapeutics (NASDAQ:ITRM) last released its earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.22. On average, analysts expect Iterum Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iterum Therapeutics Trading Down 0.7 %

Shares of ITRM stock opened at $1.39 on Tuesday. The company has a market capitalization of $31.57 million, a price-to-earnings ratio of -0.70 and a beta of 2.25. Iterum Therapeutics has a 1-year low of $0.71 and a 1-year high of $2.50. The stock’s fifty day simple moving average is $1.13 and its 200-day simple moving average is $1.25.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Iterum Therapeutics in a report on Tuesday, September 10th.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.